---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-24-000063"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:19:40.711360+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biohaven Q2 net loss $3.64/sh; pipeline highlights MoDE degrader data and FDA alignment for BHV-8000

## Summary
- Net loss of $319.8M ($3.64/sh) in Q2 2024 vs $1.32/sh in Q2 2023; cash ~$440M.
- R&D expense $314.8M includes $171.9M non-cash milestone/royalty buyback to Knopp for Kv7 platform.
- MoDE platform: Phase 1 BHV-1300 showed dose-dependent IgG reduction, no SAEs; SC formulation had 44% higher exposure vs IV.
- BHV-8000 (TYK2/JAK1) Phase 1 completed; FDA feedback enables registrational programs for Parkinson's and prevention of ARIA.
- Taldefgrobep alfa: Phase 2 obesity trial and Phase 3 SMA topline data expected in H2 2024.

## SEC filing metadata
- accession: 0001935979-24-000063
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000063/0001935979-24-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000063/bhvn-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-24-000063
- JSON: https://secwatch.observer/filing/0001935979-24-000063.json
- Plain text: https://secwatch.observer/filing/0001935979-24-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.